We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.

Search Results

Showing 1-20 of 5,450 results
  1. Murine myeloid derived suppressor cells possess a range of suppressive mechanisms—Granzyme B is not among them

    This paper addresses the controversy of Granzyme B (GzmB) expression by murine Myeloid Derived Suppressor Cells (MDSCs). MDSCs are a heterogenous...

    Ellis Tibbs, Xuefang Cao in Cancer Immunology, Immunotherapy
    Article 07 February 2022
  2. Myeloid-derived suppressor cells in cancer and cancer therapy

    Anticancer agents continue to dominate the list of newly approved drugs, approximately half of which are immunotherapies. This trend illustrates the...

    Samantha A. Lasser, Feyza G. Ozbay Kurt, ... Viktor Umansky in Nature Reviews Clinical Oncology
    Article 08 January 2024
  3. Regulation of T cells by myeloid-derived suppressor cells: emerging immunosuppressor in lung cancer

    Myeloid-derived suppressor cells (MDSCs), major components maintaining the immune suppressive microenvironment in lung cancer, are relevant to the...

    Zhong-Ning He, Chun-Yu Zhang, ... Bao-** Hua in Discover Oncology
    Article Open access 19 October 2023
  4. Tumor-associated myeloid cells in cancer immunotherapy

    Tumor-associated myeloid cells (TAMCs) are among the most important immune cell populations in the tumor microenvironment, and play a significant...

    **nyu Cheng, Huilan Wang, ... Haixia Long in Journal of Hematology & Oncology
    Article Open access 06 July 2023
  5. FFAR2 expressing myeloid-derived suppressor cells drive cancer immunoevasion

    Background

    Emerging evidences suggest that aberrant metabolites contributes to the immunosuppressive microenvironment that leads to cancer immune...

    Zeda Zhao, Juliang Qin, ... Bing Du in Journal of Hematology & Oncology
    Article Open access 24 February 2024
  6. Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy

    Immune checkpoint inhibitors targeting programmed cell death protein 1, programmed death-ligand 1, and cytotoxic T-lymphocyte-associated protein 4...

    Yi Wang, Kai Conrad Cecil Johnson, ... Zihai Li in Journal of Hematology & Oncology
    Article Open access 28 August 2022
  7. Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion

    Paradoxically, tumor development and progression can be inhibited and promoted by the immune system. After three stages of immune editing, namely,...

    Junli Lu, Yiming Luo, ... Wenjie Huang in Experimental Hematology & Oncology
    Article Open access 12 April 2024
  8. CD45 inhibition in myeloid leukaemia cells sensitizes cellular responsiveness to chemotherapy

    Myeloid malignancies are a group of blood disorders characterized by the proliferation of one or more haematopoietic myeloid cell lineages,...

    Maryam Ahmed S. Al Barashdi, Ahlam Ali, ... Ken Mills in Annals of Hematology
    Article Open access 02 November 2023
  9. Mobilization of monocytic myeloid-derived suppressor cells is regulated by PTH1R activation in bone marrow stromal cells

    Myeloid-derived suppressor cells (MDSCs) are bone marrow (BM)-derived immunosuppressive cells in the tumor microenvironment, but the mechanism of...

    Eun Jung Lee, Kyoung ** Lee, ... Serk In Park in Bone Research
    Article Open access 21 April 2023
  10. Systemic administration of STING agonist promotes myeloid cells maturation and antitumor immunity through regulating hematopoietic stem and progenitor cell fate

    STING is a pivotal mediator of effective innate and adaptive anti-tumor immunity; however, intratumoral administration of STING agonists have shown...

    Tianxiao Xu, Jie Dai, ... Jun Guo in Cancer Immunology, Immunotherapy
    Article 07 August 2023
  11. The role of myeloid-derived suppressor cells in liver cancer

    MDSCs are immature myeloid immune cells, which accumulate in models of liver cancer to reduce effector immune cell activity, contribute to immune...

    Shiyue Zhou, Zixuan Zhao, ... Yuling Qiu in Discover Oncology
    Article Open access 23 May 2023
  12. Inflammatory recruitment of healthy hematopoietic stem and progenitor cells in the acute myeloid leukemia niche

    Inflammation in the bone marrow (BM) microenvironment is a constitutive component of leukemogenesis in acute myeloid leukemia (AML). Current evidence...

    Ding-Wen Chen, Jian-Meng Fan, ... Peter Kurre in Leukemia
    Article Open access 16 January 2024
  13. Hepatic recruitment of myeloid-derived suppressor cells upon liver injury promotes both liver regeneration and fibrosis

    Background

    The liver regeneration is a highly complicated process depending on the close cooperations between the hepatocytes and non-parenchymal...

    Qiongwen Zhang, Ting Yu, ... Huashan Shi in BMC Gastroenterology
    Article Open access 14 May 2024
  14. The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis

    Immunotherapy is the main standard treatment for non-small cell lung cancer (NSCLC) patients. Immune suppressive cells in tumor microenvironment can...

    Giuseppe Bronte, Luana Calabrò, ... Lucio Crinò in Clinical and Experimental Medicine
    Article Open access 19 November 2022
  15. Overcoming resistance to immunotherapy by targeting GPR84 in myeloid-derived suppressor cells

    Myeloid-derived suppressor cells (MDSCs) were found to gradually accumulate in the orthotopic esophageal cancer mouse model during tumor progression....

    Guohui Qin, Shasha Liu, ... Yi Zhang in Signal Transduction and Targeted Therapy
    Article Open access 28 April 2023
  16. Blockade of Myd88 signaling by a novel MyD88 inhibitor prevents colitis-associated colorectal cancer development by impairing myeloid-derived suppressor cells

    Background. In cancer, myeloid-derived suppressor cells (MDSCs) are known to escape the host immune system by develo** a highly suppressive...

    Lu Wang, Dan Hu, ... Lin **e in Investigational New Drugs
    Article Open access 28 January 2022
  17. Monocytic myeloid-derived suppressor cells as an immune indicator of early diagnosis and prognosis in patients with sepsis

    Background

    Immunosuppression is a leading cause of septic death. Therefore, it is necessary to search for biomarkers that can evaluate the immune...

    Juanjuan Cui, Wen Cai, ... Weifeng Zhao in BMC Infectious Diseases
    Article Open access 13 April 2024
  18. Ginsenoside Rd Induces Differentiation of Myeloid Leukemia Cells via Regulating ERK/GSK-3β Signaling Pathway

    Objective

    To investigate the role of ginsenoside Rd (GRd) in acute myeloid leukemia (AML) cell differentiation.

    Methods

    AML cells were treated with...

    Yu-xia Jiang, Yan-na Zhao, ... Li-ming Yin in Chinese Journal of Integrative Medicine
    Article 12 December 2023
  19. HIV-1 Myeloid Reservoirs — Contributors to Viral Persistence and Pathogenesis

    Purpose of Review

    HIV reservoirs are the main barrier to cure. CD4+ T cells have been extensively studied as the primary HIV-1 reservoir. However,...

    Edna A. Ferreira, Janice E. Clements, Rebecca T. Veenhuis in Current HIV/AIDS Reports
    Article 27 February 2024
  20. Epigenetic regulation by ASXL1 in myeloid malignancies

    Myeloid malignancies are clonal hematopoietic disorders that are comprised of a spectrum of genetically heterogeneous disorders, including...

    Feng-Chun Yang, Joel Agosto-Peña in International Journal of Hematology
    Article 16 April 2023
Did you find what you were looking for? Share feedback.